ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1614

“Do You Know What I Mean?” a Tool to Understand What Lupus Patients Comprehend

Alexa Meara1, Alexa Meara1, Juliette Yedimenko2, Juliette Yedimenko3, Holly Steigelman2, Stacy P. Ardoin4 and Ellen Peters5, 1Internal Medicine/Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, 2The Ohio State University Wexner Medical Center, Columbus, OH, 3The Ohio State University, Columbus, OH, 4Pediatric & Adult Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, 5Decision Research, Eugene, OR

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Lupus and communication

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster II: Damage and Comorbidities

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Long-term SLE treatment is often complex due to changing clinical manifestations, disease fluctuation, and frequent medication changes. Treatment can be daunting especially to the 25-60% of SLE patients who have cognitive and neuropsychiatric deficits. Patients cannot collaborate in making effective and shared and informed choices with physicians without understanding their own baseline health status and treatment options. The goal of this project was to identify the level of SLE patients’ comprehension of their medication regimens and disease outcomes. To our knowledge, a disease comprehension questionnaire has never been used in SLE patients.

Methods: Patients > 18 years were recruited from The Ohio State University Lupus Vasculitis Glomerulonephritis (LVG) clinic. After IRB approval, patient demographics and medical history was collected. A 25 item true/false disease questionnaire (Tables 2) was developed, and a small focus group of SLE patients helped ensure feasibility, understanding and appropriate literacy. The comprehension questionnaire was administered to SLE patients in clinic during routine visits.

Results: 32 SLE patients completed the questionnaire. Patient characteristics are summarized in Table 1. Table 2 shows the frequency of incorrect answers. Approximately 33% of the patients did not know that heart disease was associated with SLE. Over 15% of patients did not know that SLE affected bone health and over 25% of the patients did not recognize the side of effects of prednisone. On the other hand, 100% patients recognized SLE disease manifestations and management vary.

Conclusion: One-third of SLE patients did not recognize the burden of heart or metabolic bone disease associated with the diagnosis of SLE. In addition, SLE patients did not understand the myriad possible side effects of prednisone, one of the most common drugs prescribed for SLE. Patients appeared to not appreciate the gravity of disease comorbidities and medication side affects, however, they did appreciate the heterogeneity of the disease and its treatment. Similar studies with larger samples are needed to develop educational processes that ensure patient understanding leading to improved shared decision making.

Table 1 Patient Demographics

Age, mean (years)

41

Gender % (female)

92%

Race

61% white,

39% nonwhite

Highest Education Completed

62% < / =HS, 38% > HS

Annual Household Income, median ($)

$32,500

HS (High School)

Table 2: True/ False Comprehension Questions (correct answer indicated immediately after each one)

% Incorrect

All lupus patients should be on hydroxychloroquine (or similar medication) unless your doctor tells you to stop (True)

34.4

Heart disease is the number one cause of death of lupus patients (True)

34.4

All medications have some side effects (True)

34.4

Lupus does not increase the risk of heart disease (False)

21.9

Active lupus will not affect you or the baby during pregnancy (False)

21.9

Lupus can cause weakening of your bones (True)

21.9

If you have lupus and you smoke, its no worse for you then if you have lupus and you don’t smoke (False)

15.6

Most patients need multiple medications to control their disease (True)

15.6

Controlling your lupus decreases your risk of disability (True)

12.5

Prednisone when stopped abruptly, can cause life threatening consequences (True)

12.5

If you know someone who has lupus, you can expect to have the same things happen to you (False)

9.4

Prednisone is not a steroid (False)

6.3

Exercise can improve your bone and heart health (True)

6.3

All patients with lupus will develop kidney disease (False)

6.3

Most people with lupus, when on the correct medication, can live a life similar to someone who does not have lupus (True)

6.3

Sun exposure does not increase your risk for lupus flares (False)

3.1

It is not important to monitor blood work regularly inpatients with lupus to see if their disease is active or not (False)

3.1

If your doctor suggests a medication and the medication does not work for you, then your doctor has failed you (False)

0

Lupus can never be cured, but can be managed (True)

0

Starting a new medication is a bad idea because you will definitely get the side effects (False)

0

Because your doctor prescribed a medication for you, it is guaranteed to work for you (False)

0

True/False Questions about the medication: Prednisone

(correct answer indicated immediately after each one)

% Incorrect

This medication can cause worsening acne (True)

43.8

This medication does not affect your sugars (False)

40.6

This medication can cause easy bruising (True)

34.4

This medication does not cause weight gain (False)

31.3

This medication can causes changes to your hair (True)

25.0

This medication does not disrupt your sleep (False)

18.8


Disclosure: A. Meara, None; A. Meara, None; J. Yedimenko, None; J. Yedimenko, None; H. Steigelman, None; S. P. Ardoin, not applicable, 9; E. Peters, None.

To cite this abstract in AMA style:

Meara A, Meara A, Yedimenko J, Yedimenko J, Steigelman H, Ardoin SP, Peters E. “Do You Know What I Mean?” a Tool to Understand What Lupus Patients Comprehend [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/do-you-know-what-i-mean-a-tool-to-understand-what-lupus-patients-comprehend/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/do-you-know-what-i-mean-a-tool-to-understand-what-lupus-patients-comprehend/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology